A Post Marketing Surveillance Study to Monitor the Risk of Urinary Retention in Retigabine Users
Phase of Trial: Phase IV
Latest Information Update: 28 Nov 2016
At a glance
- Drugs Retigabine (Primary) ; Antiepileptic drugs
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 28 Sep 2016 Planned End Date changed from 1 Nov 2015 to 1 Sep 2016.
- 28 Sep 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Sep 2016.
- 28 Sep 2016 Status changed from active, no longer recruiting to discontinued.